| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/28/2002 | US6395784 Obesity, hypercholesterolemia, atherosclerosis, thyroid cancer, hypothyroidism, osteoporosis, depression, arrhythmia, and congestive heart failure treatment |
| 05/28/2002 | US6395781 Reducing vascular diameter |
| 05/28/2002 | US6395771 Solvent solubility; side effect reduction |
| 05/28/2002 | US6395768 Preventing cytotoxic effect of amyloid protein; oxidation, stress resistance |
| 05/28/2002 | US6395754 Antiinflammatory agents, cardiovascular disorders, antipyretics |
| 05/28/2002 | US6395750 Drugs for the treatment of malignant tumors |
| 05/28/2002 | US6395734 Anticancer agents |
| 05/28/2002 | US6395729 Use of pyridazino[4,5-b]indole-1-acetamide derivatives for preparing medicines for treating diseases related to the dysfunction of peripheral benzodiazepin receptors |
| 05/28/2002 | US6395720 Anticancer agents |
| 05/28/2002 | US6395715 Antitumor agents |
| 05/28/2002 | US6395712 Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy |
| 05/28/2002 | US6395711 Macrolides with antitumor activity |
| 05/28/2002 | US6395510 Vertebrate apoptosis gene: compositions and methods |
| 05/28/2002 | US6395502 Method and means for modulating PGE synthase activity |
| 05/28/2002 | US6395313 Ngali nut oil |
| 05/28/2002 | US6395309 Use of an extract of Alchemilla vulgaris to inhibit angiogenesis |
| 05/28/2002 | US6395284 Mesomorphic complex of vitamin a acid and polyethyleneimine or poly-l-amino acid; treatment of skin disorders such as acne; antitumor agents |
| 05/28/2002 | US6395276 Killing malignant b cells by contacting with protein having ribonuclease activity linked to antibody against b cell surface marker; anticancer agents |
| 05/28/2002 | US6395272 Therapeutic compounds comprised of anti-Fc receptor antibodies |
| 05/28/2002 | US6395271 Culturing myecelial inoculum in potato dextrose broth, then harvesting when culture at specific redness index; antitumor agents; anticarcinogenic agents |
| 05/28/2002 | US6395267 Inhibiting signal transduction in tumor necrosis factor receptors by identifying molecule that binds to specific amino acid sequence of human receptor, then bringing molecule in contact with receptor |
| 05/28/2002 | US6395254 Diagnosis of tumors and inflammatory disease |
| 05/28/2002 | CA2217710C Cancer metastasis inhibition with n-acetylneuramic acid |
| 05/28/2002 | CA2203618C New metalloprotease inhibitors, their preparation process and the pharmaceutical compounds that contain them |
| 05/28/2002 | CA2121256C Secreted mac-2-binding glycoprotein |
| 05/28/2002 | CA2083274C The pharmacological use of certain cystine derivatives |
| 05/28/2002 | CA2073146C Octadecyl-[2-(n-methylpiperidino)-ethyl]-phosphate and a process for its preparation |
| 05/28/2002 | CA2032653C Cytotoxic lymphocyte maturation factor and monoclonal antibodies directed thereto |
| 05/28/2002 | CA1341362C Human manganese superoxide dismutase cdna, its expression in bacteria and method of recovering enzymatically active human manganese superoxide dismutase |
| 05/23/2002 | WO2002040700A2 Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| 05/23/2002 | WO2002040683A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/23/2002 | WO2002040671A2 Immunoglobulin superfamily proteins |
| 05/23/2002 | WO2002040666A2 Fat regulated genes, uses thereof, and compounds for modulating same |
| 05/23/2002 | WO2002040651A2 A human trna-specific adenosine deaminase |
| 05/23/2002 | WO2002040629A2 Promoters exhibiting endothelial cell specificity and methods of using same |
| 05/23/2002 | WO2002040545A2 Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point |
| 05/23/2002 | WO2002040540A2 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 05/23/2002 | WO2002040535A2 Compositions and methods relating to ovary specific genes and proteins |
| 05/23/2002 | WO2002040532A1 A new polypeptide-prostatic gland specific membrane antigen 9 and the polynucleotide encoding it |
| 05/23/2002 | WO2002040529A2 Diastereomeric peptides and pharmaceutical compositions comprising them |
| 05/23/2002 | WO2002040518A1 Periplasmic domain of an enterobacterium omp protein and its use as carrier or adjuvant |
| 05/23/2002 | WO2002040517A2 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | WO2002040507A2 Novel compounds for uses in radioimmunoscintigraphy and/or radioimmunotherapy of cancers |
| 05/23/2002 | WO2002040505A2 Dibenzoxazepine alpha v integrin receptor antagonist |
| 05/23/2002 | WO2002040498A2 Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides |
| 05/23/2002 | WO2002040494A1 Ruthenium-aryl-compounds in cancer therapy |
| 05/23/2002 | WO2002040489A1 Novel 4'-demethyl-4'-o-substituted-1-deoxypodophyllotoxin derivative and geometric isomer thereof, process for the preparation thereof and anti-cancer composition comprising the same |
| 05/23/2002 | WO2002040488A1 Novel photosensitizers of 9-hydroxypheophorbide-a derivatives used for photocynamic therapy |
| 05/23/2002 | WO2002040484A2 Novel imidazole derivatives, production method thereof and use thereof |
| 05/23/2002 | WO2002040477A2 Saframycins, analogues and uses thereof |
| 05/23/2002 | WO2002040475A1 Bombesin receptor antagonists |
| 05/23/2002 | WO2002040470A1 Imidazole derivatives, process for their preparation and their use |
| 05/23/2002 | WO2002040469A1 Bombesin receptor antagonists |
| 05/23/2002 | WO2002040450A1 (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors |
| 05/23/2002 | WO2002040045A2 Microspheres of pancreatic enzymes with high stability |
| 05/23/2002 | WO2002040042A2 Method for optimally delivering virus to a solid tumor mass |
| 05/23/2002 | WO2002040041A2 Orally ingestible preparation of mistletoe lectins and method |
| 05/23/2002 | WO2002040038A2 M. tuberculosis chaperonin 10 and uses thereof |
| 05/23/2002 | WO2002040037A2 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | WO2002040017A1 Cancer chemotherapeutical and chemopreventive agent |
| 05/23/2002 | WO2002040016A2 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 05/23/2002 | WO2002040003A1 Method for producing an organic solvent-free lycopene concentrate, the resulting concentrate and composition comprising said concentrate |
| 05/23/2002 | WO2002040001A2 Compositions for treatment of malignant effusions comprising a biocompatible polymer and antineoplastic taxane |
| 05/23/2002 | WO2002040000A2 Use of cci-779 as an antineoplastic agent |
| 05/23/2002 | WO2002039999A2 Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition |
| 05/23/2002 | WO2002039996A2 Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists |
| 05/23/2002 | WO2002039995A2 Combination therapy for estrogen-dependent disorders |
| 05/23/2002 | WO2002039990A2 Method for screening anti-proliferative compounds and inhibiting tumor growth |
| 05/23/2002 | WO2002039988A2 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists |
| 05/23/2002 | WO2002039976A1 Use of 2-oxothiazolidine 4-carboxylic acid derivatives as agents promoting skin peeling |
| 05/23/2002 | WO2002039975A1 Use of at least a sulphonic amino derivative in a composition promoting skin peeling |
| 05/23/2002 | WO2002039958A2 Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
| 05/23/2002 | WO2002039954A2 Novel compounds |
| 05/23/2002 | WO2002039953A2 Texaphyrin coordination compounds and uses thereof |
| 05/23/2002 | WO2002039952A2 Synergistic ecta compositions |
| 05/23/2002 | WO2002039885A2 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 05/23/2002 | WO2002016559A8 In vivo animal model of human leukemia |
| 05/23/2002 | WO2002006213A3 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| 05/23/2002 | WO2002005823A3 USE OF 2-METHYLENE-19-NOR-20(S)-1α,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH |
| 05/23/2002 | WO2002002596A3 Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them |
| 05/23/2002 | WO2002002116A3 Therapeutic treatment of cancer with a protein kinase c inhibitor |
| 05/23/2002 | WO2001096603A3 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| 05/23/2002 | WO2001093846A3 Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans |
| 05/23/2002 | WO2001092484A3 Adjuvant preparation for the induction of specific immunity |
| 05/23/2002 | WO2001092253A3 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 05/23/2002 | WO2001089494A3 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
| 05/23/2002 | WO2001087346A3 Dendritic cells loaded with toxic substances |
| 05/23/2002 | WO2001085208A3 Molecular antigen arrays and vaccines |
| 05/23/2002 | WO2001083774A3 Novel mutated form of arginine deiminase |
| 05/23/2002 | WO2001083755A3 Human anti-cd40 antibodies and methods of making and using same |
| 05/23/2002 | WO2001083719A3 25692, a novel human o-methyltransferase family member and uses thereof |
| 05/23/2002 | WO2001082948A3 Uses of tgap7 for the modulation of leucocyte activation |
| 05/23/2002 | WO2001081577A3 Dna encoding the prost 03 polypeptide |
| 05/23/2002 | WO2001081340A3 Heterocycles that are inhibitors of impdh enzyme |
| 05/23/2002 | WO2001081316A3 Substituted phenyl farnesyltransferase inhibitors |
| 05/23/2002 | WO2001079444A3 Albumin fusion proteins |
| 05/23/2002 | WO2001079180A3 5-substituted tetralones as inhibitors of ras farnesyl transferase |
| 05/23/2002 | WO2001079179A3 Dihydro-2h-naphthalene-1-one inhibitors of ras farnesyl transferase |
| 05/23/2002 | WO2001079164A3 N-substituted dithiocarbamates for the treatment of biological disorders |
| 05/23/2002 | WO2001076637A3 Peptide conjugates for drug delivery |